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Abstract
Cell penetrating peptides (CPPs) have been extensively studied in polyelectrolyte complexes as a 
means to enhance the transfection efficiency of plasmid DNA (pDNA). Increasing the molecular 
weight of CPPs often enhances gene expression, but poses a risk of increased cytotoxicity and 
immunogenicity compared to low molecular weight CCPs. Conversely, low molecular weight 
CPPs typically have low transfection efficiency due to large complex size. Complexes made using 
low molecular weight CPPs were found to be condensed to a small size by adding calcium. In this 
study, complexes of low molecular weight polyarginine and pDNA were condensed with calcium. 
These complexes showed high transfection efficiency and low cytotoxicity in A549 carcinomic 
human alveolar basal epithelial cells. The relationship between transfection efficiency and 
polyarginine size (5, 7, 9 or 11 amino acids), polyarginine/pDNA charge ratios, and calcium 
concentrations were studied. Polyarginine 7 was significantly more effective than other 
polyarginines under most formulation conditions suggesting a link between cell penetration ability 
and transfection efficiency.
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1. INTRODUCTION
Many studies have shown that nucleic acids complex electrostatically with polycations to 
form polyplexes. Unfortunately, the most effective polycations are often the most toxic. 
Polyethylenimine (PEI), polylysine and similar polycations can mediate high levels of gene 
expression, but high molecular weight polycations are often required to effectively condense 
the DNA to small particles.1–10 The needed increase in molecular weight; however, often 
increases cytotoxicity.2, 11–13 Cytotoxicity of polycations may be minimized by different 
approaches such as conjugation with hydrophilic or degradable polymers (e.g. 
hydroxypropyl methacrylamide (HPMA) or polyethylene glycol (PEG)).11, 14–16 A simple 
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alterative is to identify ways to form small polyplexes using less cytotoxic polycations such 
as cell penetrating peptides (CPPs).1, 17–19
CPPs are short sequences of amino acids characterized by their cationic or amphipathic 
nature that aid cellular uptake of different molecular cargo.1, 20–23 Two general methods 
have been examined for CPP-mediated gene delivery, which are chemical conjugation of 
CPPs with nucleic acids or complexation.11, 24–27 The negative charge of genetic material 
(e.g. DNA or siRNA) and the positive charge of CPPs can impede direct conjugation. On the 
other hand, genetic material can be electrostatically bound and neutralized when complexed 
with CPPs.1, 11, 28
The most commonly known CPPs are human immunodeficiency virus-1 (HIV-1) 
transcriptional activator (TAT) protein, and the herpes simplex virus structural protein 
VP22. Sequence similarities between TAT, and VP22 indicated the importance of basic 
amino acids, such as arginine or lysine. Short peptides containing only arginine have the 
ability to translocate through cell membranes.1, 9, 24, 29–33 Furthermore, polymers or CPPs 
with some of their residues altered with arginine or the guanidine group displayed highly 
enhanced transfection efficiency.32, 34
The size, the charge, and the molecular weight of CPPs (e.g. polyarginine) play important 
roles in condensing DNA for delivering genetic material to target cells.35 CPPs containing 
cationic amino acids such as lysine or arginine were found to complex genetic material 
efficiently.36–38 CPPs rich with arginine also tended to possess high transfection 
efficiency.39–42 Often, polyarginine peptides delivered genetic material into cells more 
efficiently than other homopolymer peptides (e.g. polylysine and polyhistidine) of equal 
length. A study also determined the uptake of different polyarginine lengths (e.g. R3, R6, 
R9, R15 and R30) and found that simply increasing the length of polyarginine did not 
necessarily increase the uptake. Polyarginines between R7 and R20 maximized uptake by 
cells.41, 43, 44 Other groups studied the translocation of different polyarginine lengths (R4, 
R6, R8, R10, R12 and R16) and found that the R8 peptide maximized cellular uptake, while 
others found R6 to R9 translocated optimally through cell membrane. An analogous result 
occurred using polyarginines to mediate protein delivery.30, 41, 44 Thus, polyarginine size is 
essential for membrane permeability.
Some reports have suggested that low molecular weight polyarginine peptides are able to 
form complexes with DNA and promote transfection in different mammalian cell 
types.32, 45–47 Although reports suggest low molecular weight polyarginine/pDNA 
complexes may achieve modest transfection with negligible cytotoxicity, the large particle 
size (microparticles) is a limitation.32 Indeed, high molecular weight polycations often have 
the ability to condense DNA into small and stable complexes while low molecular weight 
polycations often yield large and unstable complexes.32, 47–49 A major shortcoming with 
high molecular weight polyarginines is cytotoxicity; however, low molecular weight 
polyarginines (< 10 kDa) typically exhibit poor transfection efficiency.
Calcium phosphate precipitation is a well-established approach to DNA condensation and 
gene delivery. Numerous in vitro studies demonstrated that transfection efficiency of DNA 
Alhakamy and Berkland Page 2






















increased when formulated as a calcium phosphate-DNA co-precipitate. Other studies found 
that calcium chloride has a positive effect on the transfection efficiency of plasmid DNA 
(pDNA)-cationic liposome complexes.1, 50–53 Still other studies showed that calcium might 
increase the endocytosis rate or accelerate endosomal release before degradation by 
lysosomes.54, 55 While the effect of calcium on transfection is unclear, these studies 
encouraged exploration of calcium with complexes formed using CPPs, such as 
polyarginine. Consequently, calcium was found to condense these large complexes and 
increase the positive charge, which dramatically enhanced transfection.1, 11, 56 In fact, 
titrating calcium can directly affect complex size and stability. Also, released polyarginines 
may maintain CPP properties since they are not chemically conjugated using this approach.
Thus, the delivery of polyarginine/pDNA complexes condensed with calcium chloride may 
offer a safe non-viral gene delivery technique with potential for clinical application.1 This 
simple formulation (polyarginine/pDNA/Ca2+) maintained the viability of A549 lung cancer 
epithelial cells while achieving high transfection efficiency. This method also yields a small 
and stable particle size, and is suitable for delivering large amounts of genetic material. In 
order to determine the importance of polyarginine molecular weight, in vitro transfection 
efficiency studies were conducted using different polyarginines (R5, R7, R9, and R11) 
(Table 1), and different calcium chloride concentrations (0, 50, 100, 150, 300, and 600 mM).
2. MATERIALS AND METHODS
2.1. Materials
Plasmid DNA (pDNA) encoding firefly luciferase (pGL3, 4818 bp) was obtained from 
Promega (Madison, Wisconsin). The pDNA purity level was determined by UV-
Spectroscopy and agarose gel electrophoresis. Polyarginine (Arg 5, 7, 9 and 11) were 
purchased from Biomatik (Cambridge, Ontario, Canada). Branched polyethylenimine (PEI, 
25 kDa) was obtained from Sigma-Aldrich (Milwaukee, Wisconsin). A549 carcinomic 
human alveolar basal epithelial cell line was obtained from American Type Culture 
Collection (ATCC; Rockville, Maryland). The cell culture medium (F-12K Nutrient 
Mixture, Kaighn’s modified with L-glutamine) was purchased through Cellgro (Mediatech, 
Inc., Manassas, VA). Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT). 
Penicillin/Streptomycin was purchased from MB Biomedical, LLC (Solon, OH). Trypsin-
EDTA was purchased from Invitrogen (Carlsbad, CA). Luciferase Assay System Freezer 
Pack and CellTiter 96® AQueous one solution cell proliferation assay (MTS) were obtained 
from Promega (Madison, Wisconsin). BCA Protein Assay Reagent (bicinchoninic acid) was 
purchased from Thermo Fisher Scientific Inc. Tris-acetate-EDTA (TAE) Buffer (10 x) was 
purchased from Promega (Madison, Wisconsin). Sterile water (DNase, RNase free) was 
purchased from Fisher Scientific. Calcium chloride dihdrate (CaCl2. 2H2O) was purchased 
from Fisher Scientific. Agarose (Medium-EEO/Protein Electrophorisis Grade) was 
purchased from Fisher Scientific. Bench Top DNA Ladder was purchased from Promega 
(Madison, WI). SYBR Green I Nucleic Acid Gel Stain was obtained from Invitrogen 
(Carlsbad, CA).
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2.2. Preparation of Polyarginine/pDNA/Ca2+ Complexes
Polyarginine/pDNA complexes were prepared by adding 15 μL of polyarginine solution 
(different polymer nitrogen to pDNA phosphate (N/P) ratios) to 10 μL (0.1 μg/μL) of pDNA 
(TAE Buffer (1 x) was used as a solution for DNA storage), followed by fast pipetting for 
20 second. At that point, 15 μL of identified molarity (e.g., 50, 300, and 600 mM) CaCl2 
was added and mixed by fast pipetting. After preparing the complexes, they were stored at 
4°C for 20–25 minute.
2.3. Preparation of PEI/pDNA Complexes
PEI/pDNA complexes were prepared by adding 15 μL of PEI solution (N/P ratio 10) to 10 
μL (0.1 μg/μL) of pDNA followed by fast pipetting for 20 seconds. After preparing the 
complexes, they were stored at 4°C for 20–25 minutes. Complexes were prepared 
immediately before each experiment.
2.4. Agarose Gel Electrophoresis
Complexes were prepared as defined previously and subsequently 4 μL of Tris-acetate-
EDTA (TAE) buffer was added. Then, 4 μL of SYBR Green 1 was mixed with the 
complexes. Afterwards, the mixture was stored at 4°C for 20–25 minutes. After the storage, 
7 μL of 6X DNA Loading Dye was added. A one kb DNA ladder was used. The mixture 
solutions were loaded onto a 1 % agarose gel, and electrophoresed for 30 minutes at 110 V.
2.5. Size and Zeta Potential
The particle size (effective diameter (nm)) of polyarginine/pDNA complexes with or 
without calcium chloride was determined by dynamic light scattering (Brookhaven 
Instruments, Holtsville, NY). The zeta potentials of the complexes were measured by Zeta 
PALS dynamic light scattering (Brookhaven Instrument, Holtsville, NY). All samples 
intended for particle size and zeta potential measurements were prepared using 10 mM Tris 
buffer, pH 7.4.
2.6. Cell Culture
A549 carcinomic human alveolar basal epithelial cell were grown in F-12K Nutrient 
Mixture media (Kaighn’s modified with L-glutamine) with 1% (v/v) Penicillin/Streptomycin 
and 10% (v/v) fetal bovine serum (FBS) at 37°C in 5% CO2 humidified air.
2.7. Transfection Studies
A549 cells were cultured in 96-well plates for 24 hr prior to transfection. The concentration 
of the cells in every well was approximately 80,000 cells/mL. The wells were washed once 
with serum-free media (SFM) and afterwards a 100 μL sample (which consisted of 20 μL of 
complex and 80 μL of SFM) was added to each well. Subsequently, a 96-well plate was 
incubated for 5 hr in an incubator. After 5 hr incubation, the sample was replaced with 100 
μL of fresh serum medium and then incubated again for approximately 48 hr. In order to 
determine the gene expression of the complexes, the Luciferase Reporter Assay from 
Promega was used. The results of the transfections were expressed as Relative Light Units 
(RLU) per milligram (mg) of cellular protein and PEI/pDNA was used as a control. BCA 
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Protein Assay Reagent (bicinchoninic acid) was used to measure total cellular protein 
concentration in the cell extracts. The Luciferase Assay and BCA were measured by a 
microplate reader (SpectraMax; Molecular Devices Crope, CA).
2.8. Cytotoxicity Assay of Polyarginine
Cytotoxicity of polyarginines was determined using a CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay (MTS) obtained from Promega (Madison, Wisconsin). 
A549 cells were cultured in a 96-well plate as described previously. After 24 h of 
incubation, the media were replaced with a sample consisting of 100 μL of fresh serum 
medium and 20 μL of MTS. Then, the plate was incubated for 3 hr in the incubator. In order 
to determine cell viability, the absorbance of each well was measured by a microplate reader 
(SpectraMax; Molecular Devices Crope, CA) at 490 nm and normalized to untreated control 
cells.
2.9. Optical microscopy
Cells were cultured, grown and incubated as mentioned above. Then, the complexes were 
added and cells were incubated again for 5 hr and 48 hr. Data were obtained using a Zeiss 
Axiovert 100 Microscope (Axiocam HRM).
2.10. Statistical Analysis
Data were analyzed by using GraphPad software. Statistical evaluation comparing the 
significance of the difference in gene expression (RLUs/mg protein) between the means of 
two data sets was performed using an unpaired t-test. One-way ANOVA, Tukey post test 
was used to analyze the differences when more than two data sets were compared.
3. RESULTS AND DISCUSSION
Agarose gel electrophoresis studies indicated that the complexes without calcium were 
robust enough to immobilize DNA when complexed with polyarginine 7, 9 and 11. DNA 
complexes with polyarginine 5 were less stable without calcium than with calcium (Figure 
1). The ability of the four distinct molecular weights of polyarginine to form complexes with 
pDNA was also studied using agarose gel electrophoresis at N/P ratios of 5, 10, 20, 30, 40, 
and 60. Polyarginines 5, 7, 9 and 11 were complexed with pDNA at these different N/P 
ratios and then condensed with calcium chloride (300 mM) (Figure 2). The immobilization 
of pDNA indicated that different polyarginine peptides could form complexes with pDNA 
even with the lowest N/P ratio of 5.
An important characteristic of the polyarginine/pDNA/Ca2+ complex is the size. A broad 
study of the relationship between the calcium concentration (150, 300, and 600 mM) and the 
particle size was conducted. Figure 3 illustrates the particle sizes of polyarginine 5, 7, 9 and 
11 complexed with pDNA as a function of calcium chloride concentration. The 
polyarginine/pDNA complexes generally showed a decrease in particle size as calcium 
concentration increased whereas the complexes without calcium showed a large particle 
size. The total positive charge of complexes also plays an important role in transfection 
efficiency and can increase the attractive force to the negative charge of the cell surface. 
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Overall, the zeta potential of polyarginine of 5, 7, 9 and 11/pDNA complexes increased 
considerably with increasing concentration of calcium chloride. For example, the zeta 
potential of polyarginine 7/pDNA complexes increased significantly from less than 5 to 
more than 20 mV with increasing concentration of calcium chloride (Figure 4). Clearly, PEI/
pDNA complexes had the highest positive zeta potential. The lowest values were associated 
with polyarginine 5/pDNA complexes.
The cellular uptake of free polyarginine was previously reported to be proportional to the 
guanidine content.43, 57–60 Here, different polyarginines were complexed with pDNA and 
the transfection of A549 cells was studied as a function of polyarginine molecular weight, 
calcium concentration, and N/P ratio. Polyarginine/pDNA/Ca2+ complexes generally 
achieved high gene expression. Interestingly, there was no notable gene expression observed 
for the polyarginine complexes without calcium. Polyarginine 5 complexes had low gene 
expression with or without calcium. On the other hand, polyarginine 7, 9 and 11 complexes 
yielded high gene expression only when adding calcium chloride. Additionally, the 
transfection efficiency of the best polyarginine/pDNA/Ca2+ complexes was superior to PEI/
pDNA complexes. Polyarginine 7 appeared significantly effective compared to the other 
polyarginines (Figure 5). Figure 6 compares the same data to illustrate the difference in 
transfection efficiency between the polyarginine peptides at difference N/P ratios, (CaCl2 
concentration 100 and 150 mM).
Calcium is an important component to condense the complexes, yielding small complexes 
with optimized DNA release.48 Consequently, only the combination of calcium and 
polyarginine effectively boosted gene transfection. In addition, others found that the cellular 
uptake of free polyarginine 16 was considerably higher than polyarginine 8, but the 
translocation into the cytosol was less efficient than polyarginine 8. In light of this, it is 
possible that the polyarginines near 8 amino acids may mediate uptake of the complexes and 
optimize cytosolic release.30 This may help explain why polyarginine 7 had the highest gene 
expression (RLUs/mg protein) compared to other polyarginines. Moreover, Figure 7 
indicates that the transfection efficiency of pDNA/Ca2+ complexes without polyarginine 
peptides was significantly lower than the complexes with polyarginine when comparing the 
same calcium concentration.
One potential mechanism of the improved transfection may be the disintegration of these 
complexes as pH decreases (i.e. intracellular). Interestingly, data illustrated the particle size 
of the CPP/pDNA/Ca2+ complexes increased when the pH of media was decreased (pH 7 to 
4) (Supplementary Figure 1). The particle counts (kilo counts per second; Kcps) for 
complexes of polyarginine 7/pDNA with calcium in acetate buffer media (pH 7, 5 and 4) 
(Supplementary Figure 2) decreased when pH decreased. These results suggested that 
calcium condensed CPP/pDNA complexes may swelled and dissociate as pH decreased, 
which is supported by previous reports of calcium/pDNA precipitates.61
Finally, an effective gene delivery vector must be able to deliver genetic material safely to 
target cells without cytotoxicity. Arginine is converted to ornithine by an enzyme called 
arginase and ornithine is the precursor of numerous polyamines, which are essential for cell 
proliferation.62 However, high molecular weight CPPs (e.g. polyarginine) can precipitate 
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serum proteins and exhibit cytotoxicity at high concentration.27 Decreasing the molecular 
weight of polyarginine tends to decrease cytotoxicity. Here, a cytotoxicity assay was used to 
measure the cytotoxicity of free PEI and polyarginines (Figure 8). Polyarginine 5, 7, 9 and 
11 showed little evidence of cytotoxicity against A549 cells even at very high concentrations 
(1 mg/mL). These results supported the promise that polyarginine/pDNA/Ca2+ complexes 
had high transfection efficiency while maintaining low cytotoxicity.
Micrographs of A549 cells showed that PEI/pDNA complexes had a negative effect on cell 
growth compared to polyarginine/pDNA/Ca2+ complexes (Figure 9). Images of the cells 
after 5 h and 48 h were similar when incubated with PEI/pDNA complexes suggesting 
inhibition of cell growth. On the other hand, the cells proliferated as expected when 
incubated with polyarginine 7/pDNA/Ca2+ complexes. Other reports suggest that PEI 
inhibits cell proliferation and alternatively, arginine may even have a slight enhancing 
effect.48, 63, 64 Additionally, we noticed that there was no precipitation when we used the 
low concentrations of CaCl2 (≤ 300 mM), but there was precipitation with the high 
concentrations of CaCl2 (> 300 mM). Micrographs were also supported by plots of total 
protein after 48 h of incubation (Figure 10). In general, polyarginine 5, 7, 9 and 11 had 
higher protein levels than PEI and were similar to control cell cultures. This finding suggests 
that PEI transfection was artificially amplified due to inhibition of cell proliferation.
4. CONCLUSIONS
Polyarginines have been successfully used as cell penetrating peptides for delivering large 
cargo such as genetic material. Polyarginine/pDNA complexes condensed with calcium 
chloride possessed excellent transfection efficiency compared to PEI complexes in A549 
lung epithelial cells. Calcium chloride concentration played a significant role in controlling 
the complex size and charge, which were important for cell transfection. Moreover, calcium 
condensation of complexes allows the incorporation and release of low molecular weight 
polyarginine CPPs in the range of 7–11 amino acids, which may locally increase cell 
membrane permeability (e.g. within intracellular vesicles). Polyarginine 7 appeared 
especially effective compared to the other polyarginines. Polyarginine 5 was ineffective 
compared to the other polyarginines suggesting the minimum size should be > 5 amino 
acids. Furthermore, the low molecular weight polyarginine peptides (5, 7, 9 and 11) showed 
negligible cytotoxicity up to 5 mg/ml and maintained the expected cell proliferation rates. 
The incorporation of CPPs into polyelectrolyte complexes using this strategy potentially 
offers a safe and effective approach to gene delivery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to acknowledge support for this work from the Coulter Foundation, and the Higuchi Biosciences 
Center as well as additional lab funding from the American Heart Association, the NIH (R03 AR054035, P20 
RR016443 and T32 GM08359-11) and the Department of Defense. In addition, we acknowledge the support of the 
NSF (CHE 0719464) and the support of the NSF (CHE 0968972 and 0966614). We also acknowledge Faculty of 
Alhakamy and Berkland Page 7






















Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia for their support. We also thank Professor C. Russell 
Middaugh (University of Kansas) for the use of laboratory equipment.
References
1. Baoum AA, Berkland C. Calcium condensation of DNA complexed with cell-penetrating peptides 
offers efficient, noncytotoxic gene delivery. J Pharm Sci. 2011; 100(5):1637–1642. [PubMed: 
21374602] 
2. Wang CF, Lin YX, Jiang T, He F, Zhuo RX. Polyethylenimine-grafted polycarbonates as 
biodegradable polycations for gene delivery. Biomaterials. 2009; 30(27):4824–4832. [PubMed: 
19539366] 
3. Midoux P, Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. 
Bioconjug Chem. 1999; 10(3):406–411. [PubMed: 10346871] 
4. Mady M, Mohammed W, El-guendy NM, Elsayed A. Eeffect of the polymer molecular weight on 
the DNA/PEI polyplexes properties. Rom J Biophys. 2011; 21(2):151–165.
5. Godbey W, Mikos A. Recent progress in gene delivery using non-viral transfer complexes. J 
Control Release. 2001; 72(1):115–125. [PubMed: 11389990] 
6. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci. 2002; 92(2):203–217. 
[PubMed: 12532370] 
7. Felgner P, Barenholz Y, Behr J, Cheng S, Cullis P, Huang L, Jessee J, Seymour L, Szoka F, Thierry 
A. Nomenclature for synthetic gene delivery systems. Hum Gene Ther. 1997; 8(5):511–512. 
[PubMed: 9095402] 
8. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A Comprehensive Model for the 
Cellular Uptake of Cationic Cell-penetrating Peptides. Traffic. 2007; 8(7):848–866. [PubMed: 
17587406] 
9. Mann A, Thakur G, Shukla V, Singh AK, Khanduri R, Naik R, Jiang Y, Kalra N, Dwarakanath B, 
Langel U. Differences in DNA condensation and release by lysine and arginine homopeptides 
govern their DNA delivery efficiencies. Mol Pharm. 2011; 8(5):1729–1741. [PubMed: 21780847] 
10. Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E. 
Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 1997; 
4(5):409. [PubMed: 9274717] 
11. Baoum A, Ovcharenko D, Berkland C. Calcium condensed cell penetrating peptide complexes 
offer highly efficient, low toxicity gene silencing. Int J Pharm. 2012; 427(1):134–142. [PubMed: 
21856394] 
12. Mayhew E, Harlos J, Juliano R. The effect of polycations on cell membrane stability and transport 
processes. J Membr Biol. 1973; 14(1):213–228. [PubMed: 4778410] 
13. Kadlecova Z, Baldi L, Hacker D, Wurm FM, Klok HA. A Comparative Study on the in-vitro 
Cytotoxicity of Linear, Dendritic and Hyperbranched Polylysine Analogues. Biomacromolecules. 
2012
14. Greenwald R. PEG drugs: an overview. J Control Release. 2001; 74(1):159–171. [PubMed: 
11489492] 
15. Qi R, Gao Y, Tang Y, He RR, Liu TL, He Y, Sun S, Li BY, Li YB, Liu G. PEG-conjugated 
PAMAM dendrimers mediate efficient intramuscular gene expression. AAPS J. 2009; 11(3):395–
405. [PubMed: 19479387] 
16. Putnam D, Zelikin AN, Izumrudov VA, Langer R. Polyhistidine–PEG: DNA nanocomposites for 
gene delivery. Biomaterials. 2003; 24(24):4425–4433. [PubMed: 12922153] 
17. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends 
Biotechnol. 2006; 24(1):39–47. [PubMed: 16307811] 
18. Soundara Manickam D, Bisht HS, Wan L, Mao G, Oupicky D. Influence of TAT-peptide 
polymerization on properties and transfection activity of TAT/DNA polyplexes. J Control Release. 
2005; 102(1):293–306. [PubMed: 15653153] 
19. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM. Highly 
efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like 
effects before mRNA degradation. J Neurosci. 2004; 24(45):10040–10046. [PubMed: 15537872] 
Alhakamy and Berkland Page 8






















20. Mo RH, Zaro JL, Shen WC. Comparison of Cationic and Amphipathic Cell Penetrating Peptides 
for siRNA Delivery and Efficacy. Mol Pharm. 2011; 9(2):299–309. [PubMed: 22171592] 
21. Gautam A, Singh H, Tyagi A, Chaudhary K, Kumar R, Kapoor P, Raghava G. CPPsite: a curated 
database of cell penetrating peptides. Database (Oxford). 2012; 2012
22. Chiu YL, Ali A, Chu C, Cao H, Rana TM. Visualizing a correlation between siRNA localization, 
cellular uptake, and RNAi in living cells. Chem biol. 2004; 11(8):1165–1175. [PubMed: 
15324818] 
23. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, 
Divita G. A new potent secondary amphipathic cell–penetrating peptide for siRNA delivery into 
mammalian cells. Mol Ther. 2008; 17(1):95–103. [PubMed: 18957965] 
24. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles 
by cell-penetrating proteins and peptides. Adv Drug Deliver Rev. 2005; 57(4):637–651.
25. Futaki S. Oligoarginine vectors for intracellular delivery: Design and cellular-uptake mechanisms. 
Peptide Science. 2005; 84(3):241–249. [PubMed: 16333858] 
26. Munyendo WLL, Lv H, Benza-Ingoula H, Baraza LD, Zhou J. Cell penetrating peptides in the 
delivery of biopharmaceuticals. Biomolecules. 2012; 2(2):187–202. [PubMed: 24970133] 
27. Howl J, Nicholl I, Jones S. The many futures for cell-penetrating peptides: how soon is now? 
Biochem Soc Trans. 2007; 35:767–769. [PubMed: 17635144] 
28. Stevenson M, Ramos-Perez V, Singh S, Soliman M, Preece JA, Briggs SS, Read ML, Seymour 
LW. Delivery of siRNA mediated by histidine-containing reducible polycations. J Control 
Release. 2008; 130(1):46–56. [PubMed: 18571758] 
29. Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and 
small interfering RNA therapeutics for cancer. Hum Gene Ther. 2006; 17(11):1062–1076. 
[PubMed: 17032153] 
30. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides. J 
Biol Chem. 2001; 276(8):5836–5840. [PubMed: 11084031] 
31. Kim HH, Choi HS, Yang JM, Shin S. Characterization of gene delivery in vitro and in vivo by the 
arginine peptide system. Int J Pharm. 2007; 335(1):70–78. [PubMed: 17150315] 
32. Koo H, Kang H, Lee Y. Analysis of the relationship between the molecular weight and transfection 
efficiency/cytotoxicity of Poly-L-arginine on a mammalian cell line. Notes. 2009; 30(4):927.
33. Saleh AFA, Aojula HS, Pluen A. Enhancement of gene transfer using YIGSR analog of Tat-
derived peptide. Biopolymers. 2008; 89(1):62–71. [PubMed: 17902173] 
34. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-
penetrating peptides: ways to overcome endosomal entrapment. The AAPS J. 2009; 11(1):13–22.
35. Emi N, Kidoaki S, Yoshikawa K, Saito H. Gene transfer mediated by polyarginine requires a 
formation of big carrier-complex of DNA aggregate. Biochem Biophys Res Commun. 1997; 
231(2):421–424. [PubMed: 9070292] 
36. Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug 
Deliver Rev. 2005; 57(4):559–577.
37. Zhao M, Weissleder R. Intracellular cargo delivery using tat peptide and derivatives. Med Res Rev. 
2003; 24(1):1–12. [PubMed: 14595670] 
38. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, Rosenecker J. Oligomers of the 
arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J 
Biol Chem. 2003; 278(13):11411–11418. [PubMed: 12519756] 
39. Tung CH, Weissleder R. Arginine containing peptides as delivery vectors. Adv Drug Deliver Rev. 
2003; 55(2):281–294.
40. Liu BR, Lin MD, Chiang HJ, Lee HJ. Arginine-rich cell-penetrating peptides deliver gene into 
living human cells. Gene. 2012
41. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in 
cancer. BBA-Rev Cancer. 2011; 1816(2):232–246.
42. Melikov K, Chernomordik L. Arginine-rich cell penetrating peptides: from endosomal uptake to 
nuclear delivery. Cell Mol Life Sci. 2005; 62(23):2739–2749. [PubMed: 16231085] 
Alhakamy and Berkland Page 9






















43. Mitchell D, Steinman L, Kim D, Fathman C, Rothbard J. Polyarginine enters cells more efficiently 
than other polycationic homopolymers. J Peptide Res. 2002; 56(5):318–325. [PubMed: 11095185] 
44. Won YW, Kim HA, Lee M, Kim YH. Reducible poly (oligo-D-arginine) for enhanced gene 
expression in mouse lung by intratracheal injection. Mol Ther. 2009; 18(4):734–742. [PubMed: 
20029398] 
45. McKenzie DL, Collard WT, Rice KG. Comparative gene transfer efficiency of low molecular 
weight polylysine DNA-condensing peptides. J Ppeptide Res. 2003; 54(4):311–318.
46. Kim HH, Lee WS, Yang JM, Shin S. Basic peptide system for efficient delivery of foreign genes. 
BBA-Rev Cancer. 2003; 1640(2):129–136.
47. de Raad M, Teunissen EA, Lelieveld D, Egan DA, Mastrobattista E. High-content screening of 
peptide-based non-viral gene delivery systems. J Control Release. 2012; 158(3):433–442. 
[PubMed: 21983020] 
48. Khondee S, Baoum A, Siahaan TJ, Berkland C. Calcium Condensed LABL-TAT Complexes 
Effectively Target Gene Delivery to ICAM-1 Expressing Cells. Mol Pharm. 2011; 8(3):788–798. 
[PubMed: 21473630] 
49. Reschel T, Koňák Č, Oupický D, Seymour LW, Ulbrich K. Physical properties and in vitro 
transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic 
polycations. J Control Release. 2002; 81(1):201–217. [PubMed: 11992692] 
50. Loyter A, Scangos GA, Ruddle FH. Mechanisms of DNA uptake by mammalian cells: fate of 
exogenously added DNA monitored by the use of fluorescent dyes. Proc Natl Acad Sci. 1982; 
79(2):422–426. [PubMed: 6952193] 
51. Roy I, Mitra S, Maitra A, Mozumdar S. Calcium phosphate nanoparticles as novel non-viral 
vectors for targeted gene delivery. Int J Pharm. 2003; 250(1):25–33. [PubMed: 12480270] 
52. Lam AMI, Cullis PR. Calcium enhances the transfection potency of plasmid DNA–cationic 
liposome complexes. Biochim Biophys Acta. 2000; 1463(2):279–290. [PubMed: 10675506] 
53. Haberland A, Knaus T, Zaitsev SV, Stahn R, Mistry AR, Coutelle C, Haller H, Böttger M. Calcium 
ions as efficient cofactor of polycation-mediated gene transfer. Biochim Biophys Acta. 1999; 
1445(1):21–30. [PubMed: 10209255] 
54. Zaitsev S, Haberland A, Otto A, Vorob’ev V, Haller H, Böttger M. H1 and HMG17 extracted from 
calf thymus nuclei are efficient DNA carriers in gene transfer. Gene Ther. 1997; 4(6):586. 
[PubMed: 9231075] 
55. Mozafari MR. Calcium Based Non-viral Gene Delivery: An Overview of Methodology and 
Applications. Acta Med Iran. 2010; 48(3)
56. Zaitsev S, Buchwalow I, Haberland A, Tkachuk S, Zaitseva I, Haller H, Böttger M. Histone H1-
mediated transfection: role of calcium in the cellular uptake and intracellular fate of H1-DNA 
complexes. Acta Histochem. 2002; 104(1):85–92. [PubMed: 11993855] 
57. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, 
synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular 
transporters. Proc Natl Acad Sci. 2000; 97(24):13003–13008. [PubMed: 11087855] 
58. Schmidt N, Mishra A, Lai GH, Wong GCL. Arginine-rich cell-penetrating peptides. FEBS Lett. 
2010; 584(9):1806–1813. [PubMed: 19925791] 
59. Åmand HL, Rydberg HA, Fornander LH, Lincoln P, Nordén B, Esbjörner EK. Cell surface binding 
and uptake of arginine-and lysine-rich penetratin peptides in absence and presence of 
proteoglycans. BBA-Rev Cancer. 2012
60. Ye S, Tian M, Wang T, Ren L, Wang D, Shen L, Shang T. Synergistic Effects of Cell Penetrating 
Peptide Tat and Fusogenic Peptide HA2 Enhance Cellular Internalization and Gene Transduction 
of Organosilica Nanoparticles. Nanomed Nanotechnol Biol Med. 2011
61. Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phosphate nanoparticles: highly 
efficient non-viral vector for gene delivery. Int J Pharm. 2005; 288(1):157–168. [PubMed: 
15607268] 
62. Kim HH, Choi HS, Yang JM, Shin S. Characterization of gene delivery in vitro and in vivo by the 
arginine peptide system. Int J Pharm. 2007; 335(1):70–78. [PubMed: 17150315] 
Alhakamy and Berkland Page 10






















63. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast 
cancer cell lines: Nω-hydroxy-L-arginine selectively inhibits cell proliferation and induces 
apoptosis in MDA-MB-468 cells. Cancer Res. 2000; 60(12):3305–3312. [PubMed: 10866325] 
64. Lind DS. Arginine and cancer. J Neurosci. 2004; 134(10):2837S–2841S.
Alhakamy and Berkland Page 11























Agarose gels of polyarginine/pDNA complexes with and without CaCl2 (300 mM) at N/P 
ratios of 5, 10, 20, 30, 40, and 60. (A) Polyarginine 5/pDNA complexes without CaCl2 and 
(B) with CaCl2. (C) Polyarginine 7/pDNA complexes without CaCl2 and (D) with CaCl2. 
(M) Refers to marker and (C) refers to control (pDNA).
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Agarose gels of polyarginine/pDNA complexes condensed with CaCl2 (300 mM) at N/P 
ratios of 5, 10, 20, 30, 40, and 60. (A) Polyarginine 5/pDNA/Ca2+ complexes, (B) 
polyarginine 7/pDNA/Ca2+ complexes, (C) polyarginine 9/pDNA/Ca2+ complexes, and (D) 
polyarginine 11/pDNA/Ca2+ complexes. (M) Refers to marker and (C) refers to control 
(pDNA).
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Particle size (effective diameter) of polyarginine 5, 7, 9, and 11/pDNA complexes with 
different calcium chloride concentrations (0, 150, 300, and 600 mM) at (A) N/P ratio 5, and 
(B) N/P ratio 10. Results are presented as mean ± SD (n= 3).
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The effect of different calcium chloride concentrations on the zeta potential of PEI/pDNA 
complexes and polyarginine 5, 7, 9 and 11/pDNA complexes. Results are presented as mean 
± SD (n = 3).
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The transfection efficiency was determined for polyarginine/pDNA complexes at N/P ratios 
of 5, 10, 20, and 30 with different concentrations of added CaCl2 (50, 100, 150, 300, and 
600 mM). (A) Polyarginine 5/pDNA/Ca2+ complexes, (B) polyarginine 7/pDNA/Ca2+ 
complexes, (C) polyarginine 9/pDNA/Ca2+ complexes, (D) polyarginine 11/pDNA/Ca2+ 
complexes. PEI (N/P ratio 10) was used as a standard. RLUs refers to relative light units. 
Results are presented as mean ± SD (n = 4). The p of different polyarginine complexes were 
compared with PEI complexes (* = p < 0.0001, + = p < 0.008, and x = p < 0.09, t test).
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The transfection efficiency was determined for polyarginine/pDNA complexes at N/P ratios 
of 5, 10, 20, and 30 with different concentrations of added CaCl2 (100 and 150 mM) for (A) 
polyarginine 5/pDNA/Ca2+ complexes and (B) polyarginine 7/pDNA/Ca2+ complexes. PEI 
(N/P ratio 10) was used as a standard. RLUs refers to relative light units. Results are 
presented as mean ± SD (n = 4), (* = p < 0.0001, + = p < 0.005, and x = p < 0.05, one-way 
ANOVA, Tukey post test).
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The transfection efficiency was determined for pDNA/Ca2+ complexes and compared to 
polyarginine 7/pDNA/Ca2+ complexes with different concentrations of added CaCl2 (50, 
100, 150, 300, and 600 mM), (+ = p < 0.005, and x = p < 0.05, one-way ANOVA, Tukey 
post test).
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Polyarginine peptide 5, 7, 9 and 11 showed negligible cytotoxicity in comparison to PEI. 
Viability is expressed as a function of peptide concentration. Results are presented as mean 
± SD (n = 3).
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Representative images of A549 cells after incubation of PEI/pDNA complexes and 
polyarginine 7/pDNA/Ca2+ complexes. (A) PEI/pDNA complexes without calcium after 5 
hr. (B) PEI/pDNA complexes without calcium after 48 hr. (C) Polyarginine 7/pDNA 
complexes with 50 mM calcium chloride after 5 hr. (D) Polyarginine 7/pDNA complexes 
with 50 mM calcium chloride after 48 hr.
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The mass of protein after 48 hr in cell cultures treated with polyarginine/pDNA complexes 
at N/P ratios of 5, 10, 20, and 30 with different concentrations of added CaCl2 (50, 100, 150, 
300, and 600 mM). The protein level of different polyarginine/pDNA complexes was 
typically higher than PEI/pDNA complexes. (A) Polyarginine 5/pDNA/Ca2+ complexes, (B) 
polyarginine 7/pDNA/Ca2+ complexes, (C) polyarginine 9/pDNA/Ca2+ complexes, (D) 
polyarginine 11/pDNA/Ca2+ complexes.
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Table 1
Sequence and size of polyarginine 5, 7, 9 and 11.
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